Amexdrug Corporation
Amexdrug Corporation
Your view on AXRX
Overview
What the company does, where it operates, and who runs it.
About Amexdrug Corporation
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Jack Amin
- Headquarters
- 7251 Condor Street, Commerce, CA, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Jack Amin
- Headquarters
- 7251 Condor Street, Commerce, CA, US
Amexdrug Corporation, a pharmaceutical and cosmeceutical company, through its subsidiaries, primarily distributes pharmaceutical products. It is also involved in the research, development, manufacture, and sale of pharmaceutical drugs, cosmetics, and medical devices.
The company operates in two segments, Distribution and Health and Beauty Products. In addition, it engages in the distribution of prescription and over-the-counter drugs, non-drug products, and health and beauty products; and private manufacturing and labeling activities.
Further, the company manufactures and sells facial and body creams, arthritic pain relief medications, and hair and nail care products to pharmacies, beauty salons, beauty supply stores, and other fine shops. Amexdrug Corporation markets its products under the Sponix name.
The company distributes its products through its subsidiaries primarily to independent pharmacies and secondarily to small-sized pharmacy chains, alternative care facilities, and other wholesalers and retailers in the state of California.
The company was formerly known as Harlyn Products, Inc. and changed its name to Amexdrug Corporation in April 2000 to reflect the change in its business to the sale of pharmaceutical products. Amexdrug Corporation was founded in 1963 and is based in Commerce, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Amexdrug Corporation, and the rating behind it. AXRX last traded at $0.0002, 0.5× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Amexdrug Corporation. Starting points for Amexdrug Corporation: P/E 0.5, beta -0.56 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Amexdrug Corporation. Amexdrug Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Amexdrug Corporation. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Amexdrug Corporation. Amexdrug Corporation has reported as a listed company since 2001. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Amexdrug Corporation valued side by side against its closest peers. Amexdrug Corporation is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Amexdrug Corporation, and how their positions are changing. At a $33,882 market value, institutional positions materially move Amexdrug Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Amexdrug Corporation executives and directors. Shares of Amexdrug Corporation have traded between $0.0001 and $0.0020 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Amexdrug Corporation. Amexdrug Corporation is a $33,882 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Amexdrug Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Amexdrug Corporation. Coverage tracks Amexdrug Corporation within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.